WO1999005266A3 - Trans-species nuclear transfer - Google Patents
Trans-species nuclear transfer Download PDFInfo
- Publication number
- WO1999005266A3 WO1999005266A3 PCT/US1998/015387 US9815387W WO9905266A3 WO 1999005266 A3 WO1999005266 A3 WO 1999005266A3 US 9815387 W US9815387 W US 9815387W WO 9905266 A3 WO9905266 A3 WO 9905266A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nuclear transfer
- trans
- donor cells
- species nuclear
- oocytes
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 210000000287 oocyte Anatomy 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 210000002257 embryonic structure Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8771—Bovine embryos
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU85875/98A AU8587598A (en) | 1997-07-26 | 1998-07-24 | Trans-species nuclear transfer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5310397P | 1997-07-26 | 1997-07-26 | |
US60/053,103 | 1997-07-26 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999005266A2 WO1999005266A2 (en) | 1999-02-04 |
WO1999005266A3 true WO1999005266A3 (en) | 1999-04-15 |
WO1999005266B1 WO1999005266B1 (en) | 1999-09-23 |
Family
ID=21981947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/015387 WO1999005266A2 (en) | 1997-07-26 | 1998-07-24 | Trans-species nuclear transfer |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU8587598A (en) |
WO (1) | WO1999005266A2 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US7696404B2 (en) | 1996-08-19 | 2010-04-13 | Advanced Cell Technology, Inc. | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
CA2262817A1 (en) * | 1996-08-19 | 1998-02-26 | James Robl | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
JP2002505100A (en) * | 1998-03-02 | 2002-02-19 | ユニヴァーシティー オヴ マサチューセッツ アパブリック インスティテューション オヴ ハイアー エデュケイション オヴ ザ コモンウェルス オヴ マサチューセッツ リプレゼンティド バイイッツ アム | Embryonic or stem cell-like cell lines generated by interspecies nuclear transfer |
EP1067834A4 (en) * | 1998-03-16 | 2002-01-23 | Garelag Pty Ltd | Porcine nuclear transfer |
CA2334953A1 (en) * | 1999-06-30 | 2001-01-04 | Woo-Suk Hwang | Method for producing human cloned embryos by employing inter-species nuclear transplantation technique |
CN1362965A (en) | 1999-06-30 | 2002-08-07 | 先进细胞技术公司 | cytoplasmic transfer to de-differentiate recipient cells |
EP1109891A4 (en) * | 1999-06-30 | 2004-11-17 | Hwang Woo Suk | METHOD FOR PRODUCING CLONED COWS |
WO2007019398A1 (en) | 2005-08-03 | 2007-02-15 | Advanced Cell Technology, Inc. | Improved methods of reprogramming animal somatic cells |
US7621606B2 (en) | 2001-08-27 | 2009-11-24 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
NZ508739A (en) * | 1999-06-30 | 2002-11-26 | Woo Suk Hwang | Method for producing cloned tigers by employing inter-species nuclear transplantation technique |
AU7701900A (en) * | 1999-09-14 | 2001-04-17 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
BR0016561A (en) * | 1999-12-20 | 2002-09-10 | Univ Massachusetts Public Inst | Embryonic or similar cells to stem cells produced by cross-species nuclear transplants |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
RS62263B1 (en) | 2013-04-16 | 2021-09-30 | Regeneron Pharma | Targeted modification of rat genome |
BR112016013400B1 (en) | 2013-12-11 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | IN VITRO METHOD TO MODIFY A GENOME AT A GENOMIC LOCUS OF INTEREST IN A PLURIPOTENT CELL |
HUE041331T2 (en) | 2013-12-11 | 2019-05-28 | Regeneron Pharma | Methods and compositions for the targeted modification of a genome |
LT3152312T (en) | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
RS58009B1 (en) | 2014-06-26 | 2019-02-28 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
SI3221457T1 (en) | 2014-11-21 | 2019-08-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
ES2947714T3 (en) | 2014-12-19 | 2023-08-17 | Regeneron Pharma | Methods and Compositions for Targeted Genetic Modification Through Multiple Targeting in a Single Step |
ES2955841T3 (en) | 2015-03-16 | 2023-12-07 | Regeneron Pharma | Cell from a rodent that has decreased upper and lower motor neuron function and sensory perception |
BR112017025507A2 (en) | 2015-05-29 | 2018-08-07 | Regeneron Pharmaceuticals, Inc. | rodent, isolated rodent cell or isolated rodent tissue, rodent embryonic stem cell, rodent embryo, and methods for preparing a rodent and for identifying a therapeutic candidate. |
JP2019509059A (en) | 2016-02-16 | 2019-04-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Non-human animal having mutant kynureninase gene |
EP4368637A3 (en) | 2016-05-20 | 2024-07-10 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
JP2019523009A (en) | 2016-07-29 | 2019-08-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Mice having mutations leading to expression of C-terminal truncated fibrillin-1 |
JP7026678B2 (en) | 2016-09-30 | 2022-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Non-human animal with hexanucleotide repeat elongation in C9ORF72 lous coition |
CA3053386A1 (en) | 2017-02-27 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of retinoschisis |
US11696572B2 (en) | 2017-06-27 | 2023-07-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ASGR1 locus |
AU2018309714A1 (en) | 2017-07-31 | 2020-01-30 | Regeneron Pharmaceuticals, Inc. | Assessment of CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo |
BR112020001364A2 (en) | 2017-07-31 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | methods to test and modify the capacity of a crispr / cas nuclease. |
EP3585160A2 (en) | 2017-07-31 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Crispr reporter non-human animals and uses thereof |
MX394999B (en) | 2017-09-29 | 2025-03-24 | Regeneron Pharma | Non-human animals comprising a humanized |
AU2018366290B2 (en) | 2017-11-10 | 2022-01-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising Slc30a8 mutation and methods of use |
AU2018375796B2 (en) | 2017-11-30 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
CN111885915B (en) | 2018-03-19 | 2023-04-28 | 瑞泽恩制药公司 | Transcriptional modulation in animals using the CRISPR/Cas system |
US20220053741A1 (en) | 2018-09-13 | 2022-02-24 | Regeneron Pharmaceuticals, Inc. | Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy |
BR112021011703A2 (en) | 2018-12-20 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | METHODS TO PRODUCE A MODIFIED CELL AND TO EVALUATE A THERAPEUTIC CANDIDATE FOR THE TREATMENT OF A DISEASE OR CONDITION, NON-HUMAN ANIMAL OR NON-HUMAN ANIMAL CELL, NON-HUMAN ANIMAL GENOME, NON-HUMAN ANIMAL C9ORF72 GENE, AND, NUCLEASE AGENT |
CN117178959A (en) | 2019-04-04 | 2023-12-08 | 瑞泽恩制药公司 | Non-human animals including the humanized coagulation factor 12 locus |
CA3137761A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
CN114008193A (en) | 2019-06-27 | 2022-02-01 | 瑞泽恩制药公司 | Modeling of TDP-43 proteinopathy |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
CN115175559A (en) | 2020-01-28 | 2022-10-11 | 瑞泽恩制药公司 | Non-human animals comprising a humanized PNPLA3 locus and methods of use thereof |
US20230081547A1 (en) | 2020-02-07 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized klkb1 locus and methods of use |
EP4125348A1 (en) | 2020-03-23 | 2023-02-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
WO2021263146A2 (en) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
EP4426107A1 (en) | 2021-11-04 | 2024-09-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
CN118632622A (en) | 2021-12-08 | 2024-09-10 | 瑞泽恩制药公司 | Mutant myocilin disease model and its use |
WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
CN113943712B (en) * | 2021-12-20 | 2022-03-22 | 南京岚轩生物科技有限公司 | Electrofusion buffer solution, preparation method thereof and electrofusion method |
EP4475671A1 (en) | 2022-02-07 | 2024-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
JP2025506095A (en) | 2022-02-11 | 2025-03-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Compositions and methods for screening 4R tau targeting agents |
WO2023235677A1 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Animal model of tdp-43 proteinopathy |
KR20250048010A (en) | 2022-07-29 | 2025-04-07 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animals containing a modified transferrin receptor locus |
EP4565603A1 (en) | 2022-08-05 | 2025-06-11 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
US20240224964A9 (en) | 2022-09-29 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
AU2024214456A1 (en) | 2023-02-01 | 2025-07-03 | Regeneron Pharmaceuticals, Inc. | Animals comprising a modified klhdc7b locus |
WO2025006963A1 (en) | 2023-06-30 | 2025-01-02 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for increasing homology-directed repair |
WO2025122754A1 (en) | 2023-12-07 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Gaa knockout non-human animals |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496720A (en) * | 1993-02-10 | 1996-03-05 | Susko-Parrish; Joan L. | Parthenogenic oocyte activation |
WO1997007669A1 (en) * | 1995-08-31 | 1997-03-06 | Roslin Institute (Edinburgh) | Quiescent cell populations for nuclear transfer |
WO1998007841A1 (en) * | 1996-08-19 | 1998-02-26 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
WO1998030683A2 (en) * | 1997-01-10 | 1998-07-16 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts | Nuclear transfer with differentiated fetal and adult donor cells |
-
1998
- 1998-07-24 WO PCT/US1998/015387 patent/WO1999005266A2/en active Application Filing
- 1998-07-24 AU AU85875/98A patent/AU8587598A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496720A (en) * | 1993-02-10 | 1996-03-05 | Susko-Parrish; Joan L. | Parthenogenic oocyte activation |
WO1997007669A1 (en) * | 1995-08-31 | 1997-03-06 | Roslin Institute (Edinburgh) | Quiescent cell populations for nuclear transfer |
WO1998007841A1 (en) * | 1996-08-19 | 1998-02-26 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
WO1998030683A2 (en) * | 1997-01-10 | 1998-07-16 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts | Nuclear transfer with differentiated fetal and adult donor cells |
Non-Patent Citations (6)
Title |
---|
CHESNE P ET AL: "NUCLEAR TRANSFER IN CATTLE: BIRTH OF CLONED CALVES AND ESTIMATION OF BLASTOMERE TOTIPOTENCY IN MORULAE USED AS A SOURCE OF NUCLEI", LIFE SCIENCES, vol. 316, 1993, pages 487 - 491, XP000197855 * |
HEYMAN Y ET AL: "CLONING OF DOMESTIC SPECIES", ANIMAL REPRODUCTION SCIENCE, vol. 42, no. 1/04, 1996, pages 427 - 436, XP000671884 * |
SIMS M ET FIRST: "PRODUCTION OF CALVES BY TRANSFER OF NUCLEI FROM CULTURED INNER CELL MASS CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, no. 13, June 1993 (1993-06-01), pages 6143 - 6147, XP000604993 * |
STICE S L ET AL: "PLURIPOTENT BOVINE EMBRYONIC CELL LINES DIRECT EMBRYONIC DEVELOPMENT FOLLOWING NUCLEAR TRANSFER", BIOLOGY OF REPRODUCTION, vol. 54, no. 1, January 1996 (1996-01-01), pages 100 - 110, XP000671718 * |
WOLFE, B.A. ET AL.: "Embryos produced by the transfer of caprine nuclei to enucleated bovine oocytes are capable of cleavage but not to develop to blastocysts", BIOLOGY OF REPRODUCTION, vol. 50, no. suppl. 1, 1994 - 1972, pages 72, XP002092259 * |
ZAWADA, W.M. ET AL.: "Somatic cell cloned transgenic bovine neurons for transplantation in Parkinsonian rats", NATURE MEDICINE, vol. 4, no. 5, May 1998 (1998-05-01), pages 569 - 574, XP002092260 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999005266B1 (en) | 1999-09-23 |
AU8587598A (en) | 1999-02-16 |
WO1999005266A2 (en) | 1999-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999005266A3 (en) | Trans-species nuclear transfer | |
WO1998030683A3 (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
AU1595195A (en) | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals | |
EP1017423A4 (en) | Pig cloning using donor cell nuclei from differentiated cells | |
EP0938550A4 (en) | CULTURE OF A CELL LINE FROM THE INNER CELL SIZE OF HIP ANIMAL EMBRYONS. | |
WO2000031237A3 (en) | Method of cloning porcine animals | |
EP1780263A3 (en) | Method of producing an undifferentiated avian cell culture using avian primordial germ cells | |
WO2002072762A3 (en) | Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture | |
GB2350619B (en) | Sex-specific insemination of mammals with low number of sperm cells | |
AU4059089A (en) | In vitro propagation of embryonic stem cells | |
CA2263729A1 (en) | Process for producing mammals with defined genetic properties | |
NZ502712A (en) | Medium and method for long term culturing of avian primordial germ cells (PGC) in a tissue culture comprising growth factors | |
AU695398B2 (en) | Method of production of transgenic plants wholly transformed into To generation, from meristems | |
WO2001049106A3 (en) | Method for cloning animals with targetted genetic alterations | |
WO2001068831A3 (en) | Effective nuclear reprogramming in mammals | |
AU570954B2 (en) | Propagation of proliferating cell aggregates | |
IE881133L (en) | In-vitro culture of bovine embryos | |
IE890289L (en) | Bovine embryo in vitro culture | |
AU1655895A (en) | Bovine nuclear transplantation | |
Camous et al. | In vitro culture of early bovine embryos with trophoblastic vesicles: cleavage through the block stage, followed by pregnancy after transfer | |
AU3927599A (en) | Source of nuclei for nuclear transfer | |
AU6292898A (en) | Efficient nuclear transfer using primordial germ cells | |
MX9603037A (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation. | |
EP0229485A3 (en) | Growth-promoting cell culture medium and process for the cultivation of cells employing the same | |
UA12063A1 (en) | Method for cultivation of islet cells of the pancreas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09463276 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |